Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Survodutide

SYNCHRONIZE™JP

Boehringer Ingelheim · Phase 3 · Completed · Enrollment 274

NCT06176365

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Survodutide - 3.6 mgn/rn/rn/rn/r
Survodutide - 6.0 mgn/rn/rn/rn/r
Placebo groupn/rn/rn/rn/r

Not shown

  • Survodutide - 3.6 mg: endpoint not reported
  • Survodutide - 6.0 mg: endpoint not reported
  • Placebo group: endpoint not reported